<h4>Introduction</h4>Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.